e15009#Background:Multiple myeloma (MM) is a B-cell malignancy resulting from the abnormal proliferation of neoplastic plasma cells that produce monoclonal immunoglobulin (Ig). The high variability of the course of this disease, its genetic clonal heterogeneity, is due to chromosomal deletions, ...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to...
Myeloma is the second most common blood cancer, but it is not a common cancer. An estimated 32,110 new patients will be diagnosed with myeloma in the United States in 2019, and men are diagnosed with the condition slightly more frequently than women. The mortality statistic in the U.S. i...
et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225–3236 (2016). Article CAS Google Scholar Rasche, L. et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun. ...
Multiple myeloma (MM) is a cancer of plasma cell and it is the second most common blood cancer. Myeloma is a heterogeneous disease with great genetic and epigenetic complexity. Therefore, the identification of patient subgroups defined by molecular profiling and clinical features remains a critical ...
Multiple myeloma (MM) is a plasmocytemalign a n t p roliferative disease [1,2]. It causesdysplasia of clonal plasmocyte in marrow, bringsthe secretion of monoclonal immune globulinor its fragment (M protein), inducing relatedorgans or tissues lesion. MM has a diversity ofclinical features su...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Fig. 1: Important roles of miRNAs in the progression of multiple myeloma. MiRNAs are of great significance in regulating pathological factors involved in MM progressions, such as bone marrow microenvironment, methylation, immune regulation, genomic instability, and drug resistance. Meanwhile, miRNAs pres...
Sixty-three new untreated patients with multiple myeloma under the age of 70 years received C-VAMP induction treatment followed by high-dose intravenous melphalan (200 mg m(-2)) and autologous stem cell transplant, either with marrow [autologous bone marrow transplants (ABMT), n = 26] or wit...
Olechnowicz, S.W.Z., Weivoda, M.M., Lwin, S.T.et al.Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.Sci Rep9, 14189 (2019). https://doi.org/10.1038/s41598-019-50591-5 ...